secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001193125-24-010779
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus amends credit agreement: new leverage ratio 5.65x-4.00x, interest coverage 1.75x-3.00x, $10M liquidity
--------------------------------------------------------------------------------

- Bioventus LLC entered into Amendment No. 5 to Credit and Guaranty Agreement on Jan 18, 2024 with lenders and Wells Fargo as agent.
- Maximum debt leverage ratio: 5.65x for Mar 2024, stepping down to 4.00x from Jun 2025 onward.
- Minimum interest coverage ratio: 1.75x from Mar 2024, stepping up to 3.00x from Dec 2025 onward.
- New liquidity covenant requires at least $10M average daily balance per month through Oct 2025.
- Borrower paid amendment fee of 0.2% of aggregate Term Loan and Revolving Credit exposure to consenting lenders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000119312524010779/0001193125-24-010779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000119312524010779/d709819d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-010779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer